Skip to main content

Table 1 Study population characteristics

From: Identifying individuals with virologic failure after initiating effective antiretroviral therapy: The surprising value of mean corpuscular hemoglobin in a cross-sectional study

  Training Data (n = 784) Validation Data (n = 784)
Median Age (IQR) 42.4 (36.7, 47.6) 41.8 (36.2, 48.3)
Male Sex - N (%) 500 (64) 522 (67)
Race - N (%)   
   African-American 588 (75) 589 (75)
   White 169 (22) 174 (22)
   Other 27 (3) 21 (3)
HIV Risk Behaviors - N (%)*   
   MSM 203 (26) 203 (26)
   IDU 288 (37) 290 (37)
   Heterosexual 412 (53) 399 (51)
Median RNA (IQR) copies/ml** 155 (50, 6147) 145 (50, 7071)
Median CD4 (IQR) cells/ul** 273 (149, 441) 279 (133, 418)
  [N = 701 (89%)]† [N = 695 (89%)]†
Median Change in Percent CD4 (IQR)*** 2.9 (0.0, 6.7) 3.0 (-0.4, 7.3)
  [N = 655 (84%)]† [N = 635 (81%)]†
Median MCH (IQR) (pg/cell)** 33.0 (30.2, 36.6) 32.8 (29.9, 36.2)
  [N = 413 (53%)]† [N = 410 (52%)]†
Median Change in MCH (IQR)*** 1.7 (-0.2, 4.3) 1.8 (-0.3, 5.2)
  [N = 364 (46%)]† [N = 360 (46%)]†
  1. *HIV risk behaviors are reported behaviors at enrollment into the cohort and are not mutually exclusive
  2. ** At time of first HIV RNA measurement at least 4 months after initiation of effective therapy
  3. *** Change is the change from pre-HAART levels to marker measurement concurrent with HIV RNA measurement occurring at least 4 months after initiation of treatment.
  4. † The number and percent in brackets correspond to the number of individuals that were not missing these data.